Vir Biotechnology Presents New Data Evaluating the
– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomodulator...
Source: globenewswire.com
📰 Poster Presentations News
Page 3 - Poster Presentations News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Poster Presentations. Real-time updates on events, politics, business and more.
National Association of Neonatal Therapists (NANT) Announces Call for Abstracts for Annual NANT Conference
NANT is now accepting abstract submissions for Oral and Poster Presentations for the NANT 14 Conference April 11-13, 2024, in Florida.
United States Miramar Beach Champions Of Neonatal Development National Association Of Neonatal Therapists Poster Presentations Neonatal Therapists
Source: einnews.com
Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration
START study provides real-world data for AUSTEDO with the use of a 4-week patient titration kit for adults with tardive dyskinesia (TD), including utilization and patient satisfactionAUSTEDO is the only vesicular monoamine transporter 2 (VMAT2) inhibitor with 3-year long-term data1,2 approved for adults with TD and...
Source: pharmiweb.com
Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023
START study provides real-world data for AUSTEDO with the use of a 4-week patient titration kit for adults with tardive dyskinesia , including utilization and patient satisfaction AUSTEDO is the... | June 10, 2023
United States Andrew Cutler Eric Hughes Drug Administration Teva Pharmaceuticals Teva Neuroscience Inc
Source: marketscreener.com
AACR 2023 | Ascentage Pharma Presents Results from Three Studies Underscoring Exploratory Efforts in Potential New Indications
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...
Source: prnewswire.com
Investegate |Biognosys AG Announcements | Biognosys AG: Biognosys Presenting Novel Cancer Research on its Proteomics Platforms and Advancing Data Analysis with the Launch of Proteoverse™ at the AACR Annual Meeting 2023
Investegate announcements from Biognosys AG, Biognosys Presenting Novel Cancer Research on its Proteomics Platforms and Advancing Data Analysis with the Launch of Proteoverse™ at the AACR Annual Meeting 2023
United States United Kingdom Kristina Beeler Jakob Vowinckel Biognosys Truetarget Biognosys Truesignature
Source: investegate.co.uk
Biognosys AG: Biognosys Presenting Novel Cancer Research on its Proteomics Platforms and Advancing Data Analysis with the Launch of Proteoverse at the AACR Annual Meeting 2023
In collaboration with prominent biopharma companies and academic institutions, Biognosys will demonstrate the technological advances and versatility of the TrueDiscovery, TrueTarget, and TrueSignature
United Kingdom United States Biognosys Truetarget Biognosys Truediscovery Nigel Beaton Crown Bioscience
Source: finanznachrichten.de
OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 Combination Synergy with Checkpoint Inhibitor as well as Globo H-targeted CAR
OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 Combination Synergy with Checkpoint Inhibitor as well as Globo H-targeted CAR T-cell Immunotherapy
Privacy Policy Obi Pharma Poster Presentations Acr 2023 Annual Meeting Bi 999 Combination Synergy Checkpoint Inhibitor
Source: medindia.net
OBI Pharma Inc.: OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy
Poster Presentations to highlight the latest research on OBI-999's (anti-Globo H ADC) synergistic anti-tumor effect in combination with pembrolizumab and OBI's development of CAR T-cell cancer immunotherapy
Source: finanznachrichten.de
Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates
Signed exclusive worldwide license for pan-RAF inhibitor naporafenib and completed concurrent $100 million equity offering Multiple clinical data readouts planned in 2023, including for HERKULES-2,... | March 23, 2023
Source: marketscreener.com